Cystic fibrosis drug set for rejection
A €220,000 `wonder drug' to treat cystic fibrosis is set to be rejected for use in the Irish health service.
A €220,000 "wonder drug" to treat cystic fibrosis (CF) is set to be rejected for use in the Irish health service after the manufacturer was told there were serious obstacles to the Irish taxpayer covering the cost.
Kalydeco, which is manufactured by Vertex Pharmaceuticals, is the first and only drug that treats the underlying cause of CF rather than the symptoms of the condition.
It is too early to say whether Kalydeco will be a...
Subscribe from just €1 for the first month!
What's Included
With any subscription you will have access to
-
Unlimited multi-device access to our iPad, iPhone and Android Apps
-
Unlimited access to our eReader library
-
Exclusive daily insight and opinion seven days a week
-
Create alerts to never miss a subject that matters to you
-
Get access to exclusive offers for subscribers on gifts and experiences
-
Get content from Business Post, Business Post Magazines, Connected, Tatler and Food & Wine
Related Stories
The year in review
The best writing and and the biggest stories of 2019 from the Business Post
Newsround: What Thursday’s papers say
Denis O’Brien is back in court, residents continue to fight the Council on halting site and a row surfaces in government over rent control proposals
More cycle routes, expansion of Luas to Bray and new bus network proposed
Greater Dublin Area draft Transport Strategy published
